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Abstract
Purpose To determine if diminished ovarian reserve (mea-
sured by maternal antimullerian hormone (AMH) levels), is
associated with fetal aneuploidy (determined by prenatal
karyotype).
Methods This case-control study included 213 women with
singleton pregnancies who underwent both serum aneu-
ploidy screening and invasive prenatal diagnosis. 18
patients carrying an aneuploid fetus served as cases and
the remaining 195 women with a euploid fetus were
controls. Serum AMH was measured using two assays:
AMHbc (Beckman-Coulter) and AMHdsl (Diagnostic
Systems Laboratories). Karyotypes were determined by
chorionic villus sampling or amniocentesis.
Results AMHbc levels did not differ between women with
an aneuploid fetus and women with a euploid fetus (p=
0.46) and did not predict aneuploidy (ROC Area=0.57).
Additionally, AMHbc values declined significantly with
advancing gestational age.
Conclusions Maternal AMH does not appear to be a
marker of fetal aneuploidy in ongoing pregnancies. Con-
trary to previous reports, we found a significant decline in
maternal AMH levels with advancing gestational age.
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Introduction
Multiple diagnostic strategies, including follicle stimulating
hormone (FSH), estradiol, and inhibin-B measured in the
first few days of the menstrual cycle, have been used in an
effort to identify women with diminished ovarian reserve
[1, 2]. When these tests are abnormal, they often predict a
poor response to infertility treatment. Anti-mullerian hor-
mone (AMH), a homodimeric glycoprotein growth factor
within the transforming growth factor-beta family, is
synthesized by human granulosa cells in the ovary and
has exhibited significant promise as a potential marker of
ovarian reserve [2–5]. AMH appears to offer several
advantages over other traditional markers of ovarian
reserve. Studies suggest that AMH is constant throughout
the menstrual cycle and is not influenced by gonadotropin-
releasing hormone (GnRH) agonists, pregnancy, or oral
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contraceptive pills [3, 6–9]. As might be expected with a
marker of ovarian reserve, serum AMH levels decline with
age [10, 11].
From a clinical standpoint, it is unclear if diminished
ovarian reserve, particularly in younger women, is also a
proxy for egg quality. If such an association were true, then
diminished ovarian reserve could impact a woman’s risk for
fetal aneuploidy. Maternal nondisjunction during oogenesis
leads to chromosomal abnormalities in the conceptus and is
a significant cause of embryonic and fetal loss [12, 13]. The
frequency of these oocyte-related chromosomal abnormal-
ities increases with advancing maternal age [14–19]. This
increase in aneuploid oocytes parallels the diminishing
ovarian reserve, decreased fertility, and increased miscar-
riage rates that older women exhibit [20–22]. Questions
remain, however, regarding a direct relationship between
fetal aneuploidy and diminished ovarian reserve, indepen-
dent of maternal age. In other words, does diminished egg
quantity correlate with poor egg quality?
In some women, the ovarian aging process does not
always correlate with chronologic age. Consequently,
ovaries may be depleted of their oocytes at a rate faster
than that which would be predicted by age alone. In these
women who undergo accelerated ovarian aging, it is
plausible that oocyte quality is also compromised. Our
objective was to test the hypothesis that low maternal AMH
levels (an indication of ovarian aging) are associated with




This case-control study included all pregnant patients with
singleton pregnancies who underwent both maternal serum
screening between 11 and 24 weeks of gestation and
subsequent invasive prenatal diagnosis between 2004 and
2007 at the University of North Carolina (UNC). During this
time period, women were offered first or second trimester
serum screening. First trimester screening included:
pregnancy-associated plasma protein A (PAPP-A) and beta-
human chorionic gonadotropin (beta-hCG). Second trimester
screening included: maternal serum alpha-fetoprotein
(MSAFP), hCG, unconjugated estriol, and inhibin-A. The
results were immediately available to the patient and the
ordering practitioner. The unused residual portion of serum
was stored at −80°C for research purposes. Invasive prenatal
diagnosis was performed via amniocentesis or chorionic villus
sampling (CVS) at the discretion of the patient and her
healthcare providers. Prenatal karyotypes were performed
through the UNC Cytogenetics Laboratory.
Subjects were identified through the Prenatal Diagnosis
Program at UNC. To be included in our study, a subject
must have: (1) undergone serum screening for fetal
aneuploidy and CVS or amniocentesis at the UNC Prenatal
Diagnosis Center between 2004 and 2007, (2) have
sufficient stored serum available, (3) have available
cytogenetic results from CVS or amniocentesis, and (4)
have a singleton pregnancy. There were no exclusions
based on maternal age. Within the study population, cases
and controls were identified according to the results of their
fetal karyotypes. Those patients with normal fetal karyo-
types were considered controls, and those with abnormal
(aneuploid) karyotypes were considered cases. A retrospec-
tive chart review was performed on all cases and controls to
collect demographic, clinical, laboratory, and karyotypic
data. Institutional Review Board approval was obtained for
this research at the University of North Carolina at Chapel
Hill.
AMH assays
Each patient’s serum AMH level, serving as a marker of
ovarian reserve, was measured as the exposure of interest.
Serum stored in small aliquots at −80°C was thawed once
and used for the assays. AMH stability during long-term
freezer storage has previously been demonstrated [10].
Serum AMH was quantified in duplicate using two
different assays: AMHbc (Immunotech, Beckman-Coulter)
and AMHdsl (Diagnostic Systems Laboratories). Both
assays are standard dual monoclonal antibody sandwich
enzyme immunoassays which are specific for AMH and do
not exhibit any significant cross-reactivity with related
molecules. AMHbc’s lower limit of sensitivity was 0.7 pM.
Intra-assay and interassay coefficients of variation for
AMHbc were 4% and 9%, respectively. AMHdsl’s lower
limit of sensitivity was 0.017 ng/mL. Intra-assay and
interassay coefficients of variation for AMHdsl were 3%
and 5%, respectively. AMHbc and AMHdsl levels were
significantly correlated (R=0.68, p<0.001).
Statistical analysis
Our power analysis was determined by the anticipated
prevalence of fetal aneuploidy in our sample and the mean
AMH levels in the normal and abnormal groups. Assuming
AMH levels would differ, we used means in infertile
women who did not conceive (1.1±1.6 ng/mL) and means
in infertile women who did conceive (2.4±2.9 ng/mL) as
described in the Hazout et al. study to calculate sample size
[2]. We assumed an aneuploidy prevalence of 10% in this
high-risk population of women who had undergone both
serum screening and invasive prenatal diagnosis based on
our pre-study analysis. We needed 160 patients in the
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euploid group and 16 patients in the aneuploid group to
have 80% power to detect a 1.3 ng/mL difference between
the two groups at a significance level of 0.05.
Commercial statistical software (STATA 10.0; College
Station, TX) was used for the statistical analysis. Nonpara-
metric and parametric tests were performed as appropriate
for the entire study population and according to fetal
karyotype status (cases versus controls). Baseline character-
istics including demographic, clinical, and laboratory
features, were compared between cases and controls with
either a t test for continuous data or chi2 test for categorical
data. A normal distribution of AMH values was achieved
by square root transformation. Logistic regression analysis
was used to adjust for maternal age, gestational age at blood
draw, maternal weight, and smoking. A two-sided P value
less than 0.05 was considered significant.
In a sensitivity analysis, the above analysis was repeated
and only fetal trisomies were considered abnormal. Subse-
quent AMH means were compared using non-parametric
tests and logistic regression analysis with square root-
transformed AMH used to adjust for confounders.
Results
Maternal demographics in the overall study cohort (N=213)
revealed a mean age of 32.9±6.9 years, 61% were parous,
71% were privately insured, 85% were non-smokers and
the mean weight was 156.1±39.6 pounds. Four patients had
a history of fetal aneuploidy in the past. 66% of patients
had an abnormal serum screen for aneuploidy. The mean
AMHbc level for the entire cohort was 15.0±13.2 pM, and
the mean AMHdsl level was 1.67±1.30 ng/mL. A total of
eighteen patients with an aneuploid fetus were identified as
cases, and the remaining 195 women with a euploid fetus
were selected as controls. The following aneuploidies were
found in the study group: trisomy 21 (N=10), trisomy 18
(N=3), and various other chromosomal rearrangements/
inversions (N=5). Demographic characteristics of the cases
and controls are summarized in Table 1.
To determine if we should adjust for gestational age, a
bivariate analysis was conducted to determine the relation-
ship between AMH and gestational age. AMHbc values
declined significantly with advancing gestational age (p<
0.001) (Fig. 1). AMHbc values were 20.2±14.9 pM in the
first trimester and 9.7±8.4 pM in the second trimester. This
trend was not seen with AMHdsl, however (p=0.46).
In terms of our primary question, mean AMHbc levels
did not differ significantly between women with a euploid
fetus (15.2±13.3 pM) and an aneuploid fetus (13.0±
12.6 pM, p=0.46), and AMHbc levels did not predict
aneuploidy (ROCArea=0.57). Similarly, there was no
detectable difference in AMHdsl values in euploid (1.66±
1.31 ng/mL) and aneuploid pregnancies (1.73±1.25 p=
0.81). Mean AMHbc values did not differ between women
with positive maternal serum screens and women with
negative screens (15.6±14.2 pM vs. 14.4±11.0 pM, p=
0.61). In multivariate analysis, adjusting for maternal age,
maternal weight, gestational age, and smoking did not alter
the results between AMH and fetal aneuploidy.
When only trisomy pregnancies were considered as
aneuploid, mean AMHbc levels did not differ significantly
between women with a euploid fetus (15.0±13.2 pM) and
an aneuploid fetus (14.2±14.2 pM, p=0.55), and AMHbc
levels did not predict aneuploidy (ROCArea=0.55). Simi-
larly, there was no detectable difference in AMHdsl values
in euploid (1.68±1.31 ng/mL) and aneuploid pregnancies
(1.48±1.23, p=0.60). In multivariate analysis with fetal
trisomy as the outcome, adjusting for maternal age,
maternal weight, gestational age, and smoking did not alter
the results.
Discussion
In this study, maternal AMH was not a marker of fetal
aneuploidy in ongoing pregnancies. Multiple investigators
have explored the possible link between diminished ovarian
reserve and fetal aneuploidy [14, 23–31]. The results of
these studies are mixed, but several of them suggest an
association between elevated basal FSH levels and fetal
aneuploidy that might not be predicted by age alone [23,
24, 26, 30]. Because elevated FSH levels are often a late
sign of diminished ovarian reserve, we hypothesized that an
earlier, more sensitive marker of diminished ovarian reserve
might be more clearly associated with fetal aneuploidy [10,
11].
Several studies have already highlighted AMH’s poten-
tial as an early marker of ovarian reserve [2, 32–34]. To our
knowledge, there is only one study that has examined
AMH’s potential as predictor of fetal aneuploidy [31]. This
study did not find an association between maternal AMH
levels and Down syndrome. It is unclear to us, however,
whether their cases were identified through invasive
prenatal testing or by use of a Down syndrome birth
registry that only included children born with Down
syndrome and would not have taken into account the
pregnancies that were terminated prematurely once a
diagnosis of Down syndrome was made. Additionally, this
study focused on Down syndrome alone and did not
explore any association between low AMH levels and
other types of fetal aneuploidy.
Our case-control study identified aneuploid fetuses that
were diagnosed during pregnancy. Consequently, we were
able to investigate many pregnancies that were ultimately
electively terminated. In addition, we included all abnormal
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karyotypes, instead of limiting our sample to Down
syndrome alone. Finally, our results were confirmed with
two different AMH assays, thus eliminating the possibility
that our choice of assay influenced our results. Despite
some differences in study design, our findings were
consistent with previous work and lend further strength to
the conclusion that there is no association between low
AMH levels and fetal aneuploidy. In addition, a recent
study explored the relationship between AMH levels and
embryo quality [35]. Embryo quality was assessed by both
an embryo morphology score and preimplantation genetic
screening. This study found that AMH levels did not
correlate with either embryo morphology or embryo
aneuploidy and concluded that there is not a direct
relationship between egg quantity and embryo quality.
While AMH levels may not correlate with egg quality, it
is also possible that women with the lowest AMH levels
experience early pregnancy loss or do not conceive at all. In
our study, the mean AMH levels for both cases and controls
were well within the normal range and may reflect the fact
that all of our patients had conceived and sustained a
pregnancy to at least eleven weeks. Our findings suggest
that once an ongoing pregnancy has been established, there
is no difference in maternal AMH levels between aneuploid
and euploid pregnancies. Consequently, AMH is unlikely to
serve as a useful serum marker for fetal aneuploidy.
As previously discussed, AMH appears to offer several
potential advantages over other tests of ovarian reserve.
One of the touted benefits of AMH is its stability in the
non-pregnant, pregnant, and postpartum states [8, 36].
During pregnancy, maternal AMH appears to be derived
solely from maternal follicles, without any fetal contribu-
tion, thus implying that AMH is unlikely to cross or be
produced by the placenta [36]. However, we found a
significant decline (over 50% decline from the first to
second trimester) in maternal AMHbc values with advanc-
ing gestational age. Similarly, a recent longitudinal study
(using the DSL assay) found that circulating AMH levels
decline during the second and third trimesters of pregnancy
[37]. Our cross-sectional findings, in conjunction with the
recent longitudinal study, suggest that AMH values are
more dynamic in pregnancy than previously thought.
The first study of AMH in pregnancy, a cross-sectional
study including fewer than 30 patients in each group
(nonpregnant, first, second, and third trimester, and early
postpartum) found no significant differences in AMH levels
among their groups using the Immunotech assay [8]. Our
findings using the same assay differed considerably. It is
possible that geographic differences in weight gain during
pregnancy may account for the discrepancy between the
two studies. Obese women appear to have lower AMH
levels than non-obese women [37, 38]. Significant weight
gain or changes in intravascular volume during pregnancy
may, in part, account for the decline in AMH levels that we
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Gestational Age (Weeks)
Fig. 1 AMHbc values declined significantly with advancing gesta-
tional age (p<0.001)
Characteristic Controls (N=195) Cases (N=18) P-value
Maternal age (years) 33.0 (±6.9) 31.4 (7.3) 0.348
Gestational age (weeks)a 14.3 (±2.65) 15.1 (3.13) 0.277
Race/Ethnicity 0.072
White 114 (59%) 5 (28%)
Black 34 (17%) 5 (28%)
Hispanic 18 (9%) 4 (22%)
Other 29 (15%) 4 (22%)
Maternal weight (pounds) 155.2 (±37.7) 165.3 (56.7) 0.300
Primagravida 45 (23%) 1 (6%) 0.084
Nulliparous 79 (41%) 4 (22%) 0.128
Current Smoker 30 (16%) 2 (11%) 0.622
Uninsured 15 (8%) 2 (11%) 0.865
Abnormal serum screen 124 (65%) 15 (83%) 0.120
Table 1 Demographic charac-
teristics
Results are presented as mean
(±standard deviation) or n (%)
a Gestational age at the time of
serum screening
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did not weaken the association between advancing gesta-
tional age and declining AMHbc values.
Despite the dramatic decline in AMHbc levels with
advancing gestational age, AMHdsl values did not follow
the same pattern. The range for the AMHbc assay in our
pregnant cohort (0–74.65 pM) was much broader than that
of the AMHdsl assay (0–6.32 ng/mL), which may in part
explain this inconsistency. One of the only other studies to
directly compare the two assays also found a linear
relationship between the assays, but found that they differed
in prognostic value [39]. AMHbc assay values could be
used to distinguish between pregnant and non-pregnant
groups, while the AMHdsl could not.
While our results do not suggest that there is an
association between low AMH values and aneuploidy,
we cannot eliminate the possibility of a Type II error.
Based on our initial power analysis, we needed 160
patients in the euploid group and 16 patients in the
aneuploid group to have 80% power to detect a 1.3 ng/mL
difference in AMHbc means between the two groups at a
significance level of 0.05. With these assumptions, our
actual cohort should have had 85% power to detect a
difference in AMH values between the cases and controls.
Because the actual AMHbc means for the cases and
controls were much more similar than we had anticipated,
we would have needed over 260 patients in the aneuploid
group and over 2,600 patients in the normal group in order
to have 80% power to demonstrate that the means were
actually different at a significance level of 0.05. While it is
possible that our sample size was underpowered, our
findings are consistent with other available literature and
do not even show a trend to suggest that there is a direct
association between maternal AMH and embryonic or fetal
aneuploidy.
Conclusions
In summary, maternal AMH does not appear to be a marker
of fetal aneuploidy in ongoing pregnancies. A possible
association between low AMH levels and early pregnancy
loss warrants further investigation, however. The relation-
ship between egg quantity and egg quality in younger
women remains elusive, and alternative measures of oocyte
quality are clearly necessary. In addition, AMHbc values
declined with advancing gestational age in our cohort, thus
challenging the notion that AMH levels do not change
during pregnancy. Larger cohort studies are needed to
further characterize the dynamic changes in AMH values
both before and during pregnancy.
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